Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is an overlooked penny stock with a Hold rating and a $7 price target set by an analyst at Bank of America Securities, offering a 51.84% upside potential. The company showcased its AI-powered drug discovery platform, clinical pipeline, and financial position at the JP Morgan Healthcare Conference, with a $755 million cash position expected to last through 2027. Recursion Pharmaceuticals focuses on decoding biology and chemistry, specializing in drug development with a commitment to becoming a leading AI-native enterprise.

Read more at Yahoo Finance: Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In?